

Hemorif[®]

Diosmin INN 450 mg + Hesperidin INN 50 mg

COMPOSITION

Each film coated tablet contains micronised Diosmin INN 450 mg and Hesperidin INN 50 mg.

PHARMACOLOGY

Hemorif[®] is a phlebotonic drug and a vascular protecting agent. It reinforces venous tone by prolonging the activity of parietal noradrenaline. Thus **Hemorif[®]** decreases venous capacitance, venous distensibility, and venous emptying time.

Hemorif[®] protects the microcirculation by fighting the microcirculation damaging process; It combats venous inflammation by decreasing leukocyte activation, and as a consequence, by inhibiting the release of inflammatory mediators, principally free radicals and prostaglandin. Thus **Hemorif[®]** normalizes capillary permeability and strengthens capillary resistance.

Hemorif[®] acts on the lymphatic system, It improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure.

INDICATION

Acute hemorrhoidal attacks.
Chronic hemorrhoidal disease.
Organic and functional chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs, pain, nocturnal cramps.

DOSAGE & ADMINISTRATION

Tablet should be taken at meal times.
Acute hemorrhoidal attacks: 3 tablets twice daily for the first 4 days, then 2 tablets twice daily for three days and if required 1 tablet twice daily as maintenance dosage.
Chronic hemorrhoids: 1 tablet twice daily.
Chronic venous insufficiency: 1 tablet twice daily initially for seven days. Duration may be increased depending on severity.

CONTRAINDICATION & PRECAUTION

Proper data on contraindication is not available. If the hemorrhoidal symptoms do not disappear within 15 days, patient should ask doctor for advice.

SIDE EFFECT

Some cases of routine gastric disorders and neurovegetative disorders (feeling of discomfort) have been reported. In this cases discontinuation of treatment is not required.

DRUG INTERACTION

Proper data is not available.

USE IN PREGNANCY & LACTATION

Experimental studies in animal have not demonstrated any teratogenic effects and no harmful effect have been reported in women to date. Breast feeding is not recommended during treatment.

STORAGE

Store at a cool & dry place, protect from light & moisture.

HOW SUPPLIED

Hemorif[®] tablet : Box containing 30's tablets in blister pack.

Manufactured by :



SQUARE

PHARMACEUTICALS LTD.
BANGLADESH

© Registered Trade Mark.

Revision No.: 00